American International Group, Inc. Lyell Immunopharma, Inc. Transaction History

American International Group, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$1.71 - $3.07 $1,256 - $2,256	-735 Reduced 0.85%	85,524 $190,000
Q4 2023 Feb 13, 2024	SELL	$1.39 - $2.35 $483 - $817	-348 Reduced 0.4%	86,259 $167,000
Q3 2023 Nov 13, 2023	BUY	$1.45 - $3.35 $4,464 - $10,314	3,079 Added 3.69%	86,607 $127,000
Q2 2023 Aug 04, 2023	BUY	$1.89 - $3.86 $37 - $77	20 Added 0.02%	83,528 $265,000
Q1 2023 May 12, 2023	BUY	$1.97 - $3.58 $3,274 - $5,949	1,662 Added 2.03%	83,508 $197,000
Q4 2022 Feb 10, 2023	SELL	$2.78 - $8.09 $828 - $2,410	-298 Reduced 0.36%	81,846 $284,000
Q3 2022 Nov 14, 2022	BUY	$5.54 - $8.27 $6,431 - $9,601	1,161 Added 1.43%	82,144 $602,000
Q2 2022 Aug 12, 2022	BUY	$3.68 - $6.8 $27,003 - $49,898	7,338 Added 9.96%	80,983 $528,000
Q1 2022 May 13, 2022	BUY	$5.05 - $7.7 $308,489 - $470,369	61,087 Added 486.44%	73,645 $372,000
Q4 2021 Feb 11, 2022	SELL	$7.13 - $15.19 $2,680 - $5,711	-376 Reduced 2.91%	12,558 $97,000
Q3 2021 Nov 12, 2021	BUY	$11.0 - $17.95 $142,274 - $232,165	12,934 New	12,934 $191,000

121

142M

18.1K

200

Ticker LYEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 247,824,992
Market Cap $151M
Description
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.